The detail
Compounded semaglutide carries different risk profile than FDA-approved Ozempic/Wegovy. FDA does not review compounded products before sale. Risks include inconsistent dosing, unverified ingredients (semaglutide salt vs semaglutide base), and lack of long-term safety data. Verify your provider uses a licensed 503A pharmacy with outsourcing facility certification.
Historical context
Compounded semaglutide entered widespread retail availability in 2022 when Novo Nordisk's Wegovy went into chronic shortage status under FDA's 503A pharmacy exemption. The FDA declared the shortage resolved in February 2025, beginning a phased compounding wind-down. The safety question changed character mid-2024 as FDA began publishing adverse event data tied to compounded versions specifically — some traced to mishandled API sourcing from non-US suppliers.
Research landscape
Peer-reviewed data on compounded semaglutide is very limited — most RCT and registry evidence captures brand-name semaglutide (Wegovy/Ozempic). Regulators including the FDA have warned that compounded versions are not FDA-approved and that dosing errors have been reported more often with compounded than branded pens. Independent efficacy data for compounded formulations is largely anecdotal; using a LegitScript-verified pharmacy is a reasonable safety signal, not a guarantee.
What providers actually do
Telehealth providers split sharply. Network A (clinic-founded brands like Allara, Midi) generally moved away from compounded as shortage ended. Network B (DTC-tech brands like Henry, Found) maintain compounded options through Q2 2025, often citing patient cost-access concerns. Independent practitioners typically follow LegitScript verification + 503A statutory compliance as the floor for prescribing.
Subtle red flags specific to this question
- Pharmacy charges significantly less than competitors — could signal lab sourcing irregularities or uncertain potency.
- Vial appearance inconsistent batch-to-batch (color, particulates, label) — request COA (certificate of analysis).
- No clear chain of custody from API supplier to compounding pharmacy to patient — should be transparent on request.
- Provider unwilling to share which pharmacy chain fulfills — opacity is a red flag.
Sources
Was this helpful?